Welcome to our dedicated page for ALTRIA GROUP SEC filings (Ticker: MO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ALTRIA GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ALTRIA GROUP's regulatory disclosures and financial reporting.
Altria Group (MO) Q2-25 10-Q highlights
For the six months ended 6/30/25, net revenues fell 3.6% YoY to $11.36 bn while net earnings declined 41.8% to $3.46 bn (EPS $2.04 vs $3.41). The prior-year period included a $2.7 bn gain from the sale of IQOS U.S. rights. Ex-gain, operating trends were steadier: gross profit up 2.1% to $7.10 bn; operating income down 3.6% to $5.02 bn after a $873 m non-cash goodwill impairment tied to the e-vapor unit.
Segment OCI: Smokeable products rose 2.9% to $5.40 bn; oral tobacco surged 75% to $0.93 bn, offset by a $1.12 bn loss in “All Other” (e-vapor, Horizon, etc.).
Cash & leverage: Operating cash flow increased to $2.93 bn (vs $2.80 bn), but cash & equivalents dropped to $1.29 bn from $3.13 bn at 12/31/24 following $600 m of share buybacks and $1.61 bn debt repayment. Long-term debt stands at $23.65 bn; book equity remains negative at $(3.21) bn.
Capital returns: A new $1 bn repurchase program was authorized in Jan-25; $0.6 bn completed, $0.4 bn remains. Dividends declared YTD totaled $3.45 bn ($2.04 / share).
Key events: • ITC exclusion order removed NJOY ACE from U.S. market, triggering the goodwill write-down. • No new share restrictions on subsidiaries’ dividend capacity. • Contingent consideration for NJOY flavor PMT approvals increased by $25 m to $45 m.
Liquidity appears sufficient with $2.6 bn unused under an October-2028 revolving credit facility, but ongoing litigation and regulatory actions remain contingencies.